Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Study Information
Alliance Study ID: CALGB-50901
NCT Study ID (ClinicalTrials.gov): NCT01190449
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Cara A. Rosenbaum, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
PURPOSE: This randomized phase II trial is studying ofatumumab to see how well it works in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information